JOURNAVX
An oral tablet containing suzetrigine from Vertex Pharmaceuticals. It is a non-opioid analgesic that targets the NaV1.8 voltage-gated sodium channel and was approved by the US FDA in 2025.
- Product type
- Non-opioid analgesic (NaV1.8 inhibitor)
- Ingredients
- Suzetrigine 50 mg
- Line-up / Units
- JOURNAVX Tablets 50mg
- Form
- Tablet, 50 mg
- Manufacturer
- Vertex Pharmaceuticals
- Country of origin
- United States
Key points
- Active ingredient: suzetrigine 50 mg
- Selective NaV1.8 inhibitor
- US FDA approved (2025)
Contact us for pricing and terms